

RoosterGEM™


A COMPLETE GENETIC ENGINEERING MEDIUM



Engineered from the ground up, RoosterGEM and GMP RoosterGEM-CC are complete media built to solve key challenges in both viral and non-viral MSC and cell engineering processes.

Traditionally, genetic modification of primary cells has low efficiency of transfer requiring increased viral and non-viral agent costs, with significant time and resources allocated to media and process optimization.

RoosterGEM is a complete, off-the-shelf Genetic Engineering Medium, formulated to increase both viral and non-viral engineering efficiencies and enabling a reduction in key genetic material costs. When paired with RoosterBio's industrialized supply chain of high-volume Xeno-free hMSCs, ultra-productive expansion media, and cGMP-compatible processes — you enlist an end-to-end translation ready Genetic Engineering MSC-platform for cell or exosome engineering and streamline your path to clinical translation.



*To maximize final product yield contact RoosterBio for information on low PDL cell banks




Fig 2: Increased transient transfection efficiencies were achieved in RoosterBio's XF RoosterVial hMSCs using RoosterGEM.

PROVIDING 4-FOLD CELL ENGINEERING EFFICIENCY WHILE REDUCING YOUR WEDIA & VECTOR COSTS BY Fresults are donor and viral agent dependent.

PRODUCT FEATURES

Xeno-Free | Chemically Defined | Complete

Increased Viral and Non-viral Primary Cell Engineering Efficiency

200 Standard Reactions

cGMP Compliant Format

PRODUCT BENEFITS



Simplifies Cell Engineering Workflows



Reduces Key Genetic Modification Material Costs



Ready for Translational Applications



Part of End-to-End Genetically Modified MSC/Exosome Platform


CONTACT US FOR DETAILED CELL ENGINEERING PROCESS RECOMMENDATIONS.




PART OF A COMPLETE SYSTEM FOR hMSC GENETIC ENGINEERING TO SUPPORT CLINICAL ENGINEERED CELL BANK DEVELOPMENT

Applications for RoosterGEM™

GENETIC ENGINEERING | CELL THERAPY | EXTRACELLULAR VESICLES








Fig 4. Lentiviral transduction efficiency at Low MOI (rLV.EF1.ZsGreen1-9, MOI = 2, Flash Therapeutics) was increased by 3 to 6-fold compared to traditional serum and xeno-free media system. This reduction in MOI dramatically reduced lentiviral associated costs.

Fig 5. Increased transduction efficiencies were achieved in RoosterBio's Xeno-free RoosterVial™ hMSCs from multiple donors and tissue sources.

PRODUCT INFORMATION

PRODUCT	SKU / CATALOG #	UNIT SIZE	INTENDED USE
RoosterGEM	M40200	200 mL bottle	For Research Use Only
RoosterGEM-CC	M03001	GMP 200 mL bottle	For Further Manufacturing Use Only

